- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00454532
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
February 27, 2012 updated by: Bionovo
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.
BZL 101 is an aqueous extract from herba Scutellaria Barbata D. Don of the Lamiaceae family.
Preclinical studies suggest that this herb has antitumor activity for breast cancer and preliminary clinical data suggest that it is tolerable in patients with metastatic breast cancer.
The overall goals of this Phase I/II trial are to assess the toxicity, maximum tolerated dose, safety and preliminary efficacy of BZL101 for the treatment of advanced metastatic breast cancer.
Study Overview
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Key Inclusion Criteria:
- Women 18 years or older
- Histologically confirmed breast cancer
- Clinical evidence of metastatic (stage IV) metastasis (other than bone metastasis)
- Availability of estrogen and progesterone receptor status
- At least one measurable disease site defined by RECIST criteria, 30 days prior to study therapy
- For the phase 1, no more that 3 prior cytotoxic regimens for metastatic breast cancer. For the phase 2, no more than 2 prior cytotoxic regimens for metastatic breast cancer
- Life expectancy ≥ 12 weeks
- Eastern Cooperative Oncology Group performance status ≤2
- Women of child bearing potential must agree to 2 forms of contraception during the course of the trial.
Key Exclusion Criteria:
- Inability to understand/unwillingness to sign a written informed consent
- Any significant side effects related to prior chemo, radiation, biology or hormonal therapy that did not resolve in the judgment of the investigator
- Currently using an investigational agent
- Clinically significant gastrointestinal abnormalities
- Currently using coumadin at therapeutic doses or within 2 weeks of taking study medication
- Concurrent palliative radiation or anti-cancer treatment
- Women who report pregnancy, are breast-feeding or have a positive pregnancy test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity Based Upon Adverse Events Classifed by the NCI Common Terminology Criteria Version 3 (Phase 1)
Time Frame: Monthly
|
Dose-Limiting Toxicities graded according to Common Terminology Criteria for Adverse Events, version 3.0
|
Monthly
|
Response Evaluation Criteria In Solid Tumors (RECIST) (Phase 2)
Time Frame: 2 Months
|
Best Overall Tumor Response - Investigator Assessment
|
2 Months
|
Response Evaluation Criteria In Solid Tumors (RECIST) (Phase 2)
Time Frame: 2 months
|
Best Overall Tumor Response - Independent Radiology Assessment
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charles Shapiro, MD, Ohio State University
- Principal Investigator: Deborah Grady, M.D., University of California, San Francisco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
March 26, 2007
First Submitted That Met QC Criteria
March 29, 2007
First Posted (Estimate)
March 30, 2007
Study Record Updates
Last Update Posted (Estimate)
March 16, 2012
Last Update Submitted That Met QC Criteria
February 27, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BZL-101-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
Clinical Trials on BZL101
-
BionovoUnknownMetastatic Breast CancerUnited States